Treatment of leukemia cells with the PD173074 inhibitor, which binds the ATP pocket of FGFR2, prevents FGF2-mediated nuclear entry of pFGFR2 and, consequently, also transcriptional activation of MLL-AF4 target genes (Figure 7B). This evidence concerns the gene KMT2A and leukemia.